What is the current stock price of Lumos Diagnostics Holdings Limited (LDXHF)?

As of the latest market data, Lumos Diagnostics Holdings Limited (LDXHF) is trading at $0.13. The stock has seen a gain of 3.53% today.

Does Lumos Diagnostics Holdings Limited (LDXHF) pay a dividend?

Based on current data, Lumos Diagnostics Holdings Limited does not have a confirmed active dividend policy.

What is the market cap of Lumos Diagnostics Holdings Limited?

The current market capitalization of Lumos Diagnostics Holdings Limited (LDXHF) is approximately unavailable.

LDXHF

Lumos Diagnostics Holdings Limited·Healthcare

0.13

3.529%(+0.00)

Close Price

0.15

11.818%(+0.02)

Pre-Market

Last Updated: — ET

52W L: $0.0152W H: $0.24

LDXHF NEWS

proactiveinvestors.com

6d ago

Lumos Diagnostics lands Micro-Pak manufacturing deal with first US$250k order

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured a new three-year contract manufacturing agreement with Micro-Pak, marking a further step in...

proactiveinvestors.com

Apr 6

Goldman Sachs, Morgan Stanley seen riding trading boom as dealmaking holds firm, Jefferies says

Goldman Sachs Group Inc (NYSE:GS, XETRA:GOS) and Morgan Stanley (NYSE:MS) are set to post strong first-quarter results, driven by a surge in trading...

proactiveinvestors.com

Apr 6

Apple MacBook Neo could expand market reach, says Bank of America

Apple Inc (NASDAQ:AAPL, XETRA:APC) is positioning itself to capture a broader segment of the personal computer market with its newly launched MacBook Neo,...

proactiveinvestors.com

Apr 6

Booking Holdings completes 25-for-1 stock split

Booking Holdings Inc (NASDAQ:BKNG, XETRA:PCE1) has completed a 25-for-1 stock split, reducing its stock price from above $4,000 to about $170 on Monday. As...

proactiveinvestors.com

Apr 2

Lumos Diagnostics targets US breakthrough as FebriDx clearance unlocks billion-dollar opportunity

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into a pivotal phase, with its flagship FebriDx test gaining the regulatory clearance needed...

proactiveinvestors.com

Apr 1

Lumos lands largest FebriDx order after FDA waiver expands US market

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received its largest purchase order to date for the FebriDx® rapid respiratory infection test, with...

Company Profile

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

2021-09-22

Beta

0.81

Websitelumosdiagnostics.com↗